Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some find tumor cells and help kill them or carry tumor-killing substances to them.
Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also
stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in
chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy
uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with cisplatin,
etoposide, and radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with cisplatin,
etoposide, and radiation therapy works in treating patients with limited-stage small cell
lung cancer.